Login to Your Account

Clinic Roundup

Tuesday, January 25, 2011
Raptor Pharmaceutical Corp., of Novato, Calif., completed enrollment in a Phase III study of its delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription